• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: clinical trials will continue to play a key role in oncology device market

Report: clinical trials will continue to play a key role in oncology device market

September 10, 2014
CenterWatch Staff

The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.

Other key findings include the importance of clinical trials—although many clinical studies have been performed to demonstrate the efficacy of interventional oncology devices, further studies are required for head-to-head device comparisons.

There also is demand for studies supporting effectiveness in new indications such as breast cancer, melanoma and neuroendocrine tumors. Large-scale trials also will be useful for driving adoption of combination treatments that use both ablation and embolization products.

Microwave ablation will experience the strongest growth of all interventional oncology device segments. This treatment offers the same benefits as radiofrequency ablation but boasts larger ablation zones, faster treatment times and more complete tumor destruction.

Radioembolization spheres and drug-eluting beads (DEBs) are seeing increasing interest, particularly with interventional radiologists for the treatment of liver cancer tumors. Growth may be fueled further if these products demonstrate levels of efficacy in clinical trials that support their use as first-line therapies.

Naushad Budhwani, Decision Resources Group analyst, said, "Partnerships, mergers and acquisitions in the interventional oncology device market are prominent as competitors attempt to penetrate untapped markets in the U.S. For example, AngioDynamics acquired Microsulis Medical to add microwave ablation to its ablation portfolio, BTG acquired Therasphere to add radioembolization particles to its embolization product line containing DEBs and microspheres and a distribution agreement was established between HS Medical and HealthTronics, which gives HealthTronics a growing thermal ablation product alongside its cryoablation products."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing